DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Griscelli syndrome type 3 — screening already-approved drugs against its 22-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGriscelli syndrome type 3 maps to a 22-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for griscelli syndrome type 3 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
endothelin receptor type B (EDNRB) — EDNRB is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6IGK · 2.0 Å · ligand (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate (OLC). Experimental structure, not a prediction.
What the evidence adds up to
Griscelli syndrome type 3 is the least reported variant of this rare autosomal recessive disorder. A 2019 report describes a 23-year-old male with sporadic light-coloured skin and silver gray hair as the only features. The 2007 report of a 20-year-old female with Griscelli syndrome notes diffuse pigment dilution plus circumscribed pigment loss over thighs and abdomen, and an accelerated phase with neurological deterioration; survival beyond the first decade without specific therapy was considered a distinctive feature. That 2007 case does not specify which type, but type 3 is defined by pigmentary dilution alone with excellent prognosis, whereas the 2019 case fits that description.
Griscelli syndrome type 2, caused by RAB27A mutations, is the most common type and carries a poor prognosis. A 2012 study of six GS type 2 cases found missense mutations (L26P and L130P) in two cases, a 5-base deletion (514delCAAGC) in two cases, and a 1-base deletion (148delA) in two cases. A 2017 report notes that GS type 2 is characterised by partial albinism, immunodeficiency, organomegaly, and hemophagocytic lymphohistiocytosis (HLH), and that in most cases it leads to death within the first decade of life. A 2025 report of two siblings with GS type 2 states that both were lost to the condition, that HLH complications drive the high mortality rate, and that haematopoietic stem cell transplantation (HSCT) is currently the sole curative treatment.
No drug therapy is mentioned in any of these abstracts. The 2007 abstract states that survival beyond the first decade without specific therapy was a distinctive feature in one case, but that case is not clearly type 3. What remains missing is any clinical trial of a drug for any Griscelli syndrome type, any systematic collection of long-term outcomes for type 3 patients, and any stratification of type 3 by specific gene mutation to confirm that the mild prognosis is universal.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Griscelli syndrome: A new phenotype with circumscribed pigment loss?
AbstractGriscelli syndrome is a rare genetic immunodeficiency disorder characterized by pigment dilution, recurrent cutaneous and pulmonary infections, neurological deterioration, hypogammaglobulinemia, and defective cell-mediated immunity. Mutations of three distinct genes have been described in Griscelli syndrome with different phenotypes. The disease is usually fatal by the first decade of life. We report a 20-year-old female with Griscelli syndrome with circumscribed pigment loss over thighs and abdomen in addition to diffuse pigment dilution. An accelerated phase, similar to that described in Chediak-Higashi syndrome, was also observed in our case in the form of neurological deterioration. Survival of the patient beyond the first decade of life in the absence of specific therapy was also a distinctive feature.
Journal of Pediatric Hematology/Oncology · 2012 · 15 citations
Molecular Analysis and Clinical Findings of Griscelli Syndrome Patients
AbstractGriscelli syndrome (GS) is a rare autosomal recessive disorder associated with skin or hair hypopigmentation, hepatosplenomegaly, pancytopenia, and immunologic and central nervous system abnormalities. GS type II is caused by RAB27A mutations. We present RAB27A mutation analysis of 6 cases diagnosed as GS type II. Missense mutations (L26P and L130P) in 2 cases, deletion of 5 bases (514delCAAGC) in 2 cases, and 1 base deletion (148delA) in 2 cases were detected. This report has importance in phenotype-genotype correlation of different types of mutations including missense mutations and deletions within the RAB27A gene in GSII syndrome.
Pigment International · 2019 · 1 citations · open access
Griscelli syndrome 3: a rare and mild variant
AbstractGriscelli syndrome is a multisystemic disorder. It is of three types with a common feature of pigmentary dilution. The clinical types depend on the gene involved leading to a varied presentation ranging from only pigmentary dilution and excellent prognosis in type 3 to a severe disease with multisystem involvement in type 2. Type 3 is the least reported variant. We describe a 23-year-old male with sporadic presence of light-colored skin and silver gray hair.
AbstractGriscelli syndrome (GS) is a rare autosomal recessive disorder characterized by pigmentary dilution of the hair and skin. Three different types (1–3) caused by mutation in three different genes have been described. GS2 is characterized by partial albinism, immunodeficiency, organomegaly, and hemophagocytic lymphohistiocytosis (HLH). Long-term prognosis of GS2 is poor, and in most cases, it leads to death within the first decade of life. GS2 is most common among three types with 11 cases reported from the Indian literature. We report a case of GS2 which was diagnosed well before the development of life-threatening HLH.
International Journal of Contemporary Pediatrics · 2025 · 0 citations · open access
Griscelli syndrome type 2: a tragic tale of two siblings
AbstractGriscelli syndrome (GS) is a rare autosomal recessive disorder classified as an inborn error of immunity. Among its three variants, GS type 2, caused by mutations in the RAB27A gene, is marked by partial albinism and recurrent episodes of hemophagocytic lymphohistiocytosis (HLH). This case report chronicles the poignant journey of two siblings tragically lost to this condition. GS type 2 carries a high mortality rate, primarily due to HLH complications. Currently, hematopoietic stem cell transplantation (HSCT) remains the sole curative treatment for this devastating syndrome.
Immunology and Genetics Journal · 2020 · 0 citations
A Griscelli Syndrome, with Retropharyngeal Abscess, as First Clinical
AbstractGriscelli syndrome is a rare autosomal recessive disorder characterized by albinism with immunodeficiency, which usually causes death by early childhood. This syndrome is a primary immune defects that presents with a dilution of pigmentations of the skin and hair, recurrent pulmonary and skin infections, neurologic disorders, hypogammaglobulinemia, and variable cellular immunodeficiency. In different phenotypes of the syndrome, three mutations have been mentioned. In most of them, GS leads to death in the first decade of life. Herein, we report a one-year-old male child with an upper respiratory infection and retropharyngeal abscess as first clinical manifestation.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
